108 related articles for article (PubMed ID: 23799412)
41. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape.
Ferris RL; Jaffee EM; Ferrone S
J Clin Oncol; 2010 Oct; 28(28):4390-9. PubMed ID: 20697078
[TBL] [Abstract][Full Text] [Related]
42. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Cheson BD
J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
[TBL] [Abstract][Full Text] [Related]
43. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response.
Abès R; Gélizé E; Fridman WH; Teillaud JL
Blood; 2010 Aug; 116(6):926-34. PubMed ID: 20439625
[TBL] [Abstract][Full Text] [Related]
44. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
45. Characterization of a rituximab variant with potent antitumor activity against rituximab-resistant B-cell lymphoma.
Li B; Zhao L; Guo H; Wang C; Zhang X; Wu L; Chen L; Tong Q; Qian W; Wang H; Guo Y
Blood; 2009 Dec; 114(24):5007-15. PubMed ID: 19828699
[TBL] [Abstract][Full Text] [Related]
46. Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab.
Weng WK; Levy R
Leuk Lymphoma; 2009 May; 50(5):723-7. PubMed ID: 19452316
[TBL] [Abstract][Full Text] [Related]
47. Fcgamma receptors: structure, function and role as genetic risk factors in SLE.
Li X; Ptacek TS; Brown EE; Edberg JC
Genes Immun; 2009 Jul; 10(5):380-9. PubMed ID: 19421223
[TBL] [Abstract][Full Text] [Related]
48. Impaired development of human Th1 cells in patients with deficient expression of STAT4.
Chang HC; Han L; Goswami R; Nguyen ET; Pelloso D; Robertson MJ; Kaplan MH
Blood; 2009 Jun; 113(23):5887-90. PubMed ID: 19359411
[TBL] [Abstract][Full Text] [Related]
49. Rituximab immunotherapy results in the induction of a lymphoma idiotype-specific T-cell response in patients with follicular lymphoma: support for a "vaccinal effect" of rituximab.
Hilchey SP; Hyrien O; Mosmann TR; Livingstone AM; Friedberg JW; Young F; Fisher RI; Kelleher RJ; Bankert RB; Bernstein SH
Blood; 2009 Apr; 113(16):3809-12. PubMed ID: 19196657
[TBL] [Abstract][Full Text] [Related]
50. Secretion of interferon-gamma by human macrophages demonstrated at the single-cell level after costimulation with interleukin (IL)-12 plus IL-18.
Darwich L; Coma G; Peña R; Bellido R; Blanco EJ; Este JA; Borras FE; Clotet B; Ruiz L; Rosell A; Andreo F; Parkhouse RM; Bofill M
Immunology; 2009 Mar; 126(3):386-93. PubMed ID: 18759749
[TBL] [Abstract][Full Text] [Related]
51. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.
Marcus R; Imrie K; Solal-Celigny P; Catalano JV; Dmoszynska A; Raposo JC; Offner FC; Gomez-Codina J; Belch A; Cunningham D; Wassner-Fritsch E; Stein G
J Clin Oncol; 2008 Oct; 26(28):4579-86. PubMed ID: 18662969
[TBL] [Abstract][Full Text] [Related]
52. Human natural killer cells.
Caligiuri MA
Blood; 2008 Aug; 112(3):461-9. PubMed ID: 18650461
[TBL] [Abstract][Full Text] [Related]
53. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM
Clin Cancer Res; 2008 Jun; 14(11):3462-9. PubMed ID: 18519778
[TBL] [Abstract][Full Text] [Related]
54. Granulocyte-macrophage colony-stimulating factor potentiates rituximab in patients with relapsed follicular lymphoma: results of a phase II study.
Cartron G; Zhao-Yang L; Baudard M; Kanouni T; Rouillé V; Quittet P; Klein B; Rossi JF
J Clin Oncol; 2008 Jun; 26(16):2725-31. PubMed ID: 18427151
[TBL] [Abstract][Full Text] [Related]
55. First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial.
Hagenbeek A; Gadeberg O; Johnson P; Pedersen LM; Walewski J; Hellmann A; Link BK; Robak T; Wojtukiewicz M; Pfreundschuh M; Kneba M; Engert A; Sonneveld P; Flensburg M; Petersen J; Losic N; Radford J
Blood; 2008 Jun; 111(12):5486-95. PubMed ID: 18390837
[TBL] [Abstract][Full Text] [Related]
56. Rituximab therapy in malignant lymphoma.
Coiffier B
Oncogene; 2007 May; 26(25):3603-13. PubMed ID: 17530014
[TBL] [Abstract][Full Text] [Related]
57. A phase 2 study of rituximab in combination with recombinant interleukin-2 for rituximab-refractory indolent non-Hodgkin's lymphoma.
Khan KD; Emmanouilides C; Benson DM; Hurst D; Garcia P; Michelson G; Milan S; Ferketich AK; Piro L; Leonard JP; Porcu P; Eisenbeis CF; Banks AL; Chen L; Byrd JC; Caligiuri MA
Clin Cancer Res; 2006 Dec; 12(23):7046-53. PubMed ID: 17145827
[TBL] [Abstract][Full Text] [Related]
58. The paradox of pro-inflammatory cytokines in cancer.
Dinarello CA
Cancer Metastasis Rev; 2006 Sep; 25(3):307-13. PubMed ID: 17029030
[TBL] [Abstract][Full Text] [Related]
59. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression.
Vidal-Vanaclocha F; Mendoza L; Telleria N; Salado C; Valcárcel M; Gallot N; Carrascal T; Egilegor E; Beaskoetxea J; Dinarello CA
Cancer Metastasis Rev; 2006 Sep; 25(3):417-34. PubMed ID: 17001512
[TBL] [Abstract][Full Text] [Related]
60. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
